As expected, in our study, a significantly higher percentage of CD3+CD161+ cells was observed in the ex vivo samples from RRMS patients compared to HC (Figures 3A, 4A). This evidence concerns the gene KLRB1 and relapsing-remitting multiple sclerosis.